Allyson Kaye, MBE, Chair
Allyson lost her mother to ovarian cancer 30 years ago. Subsequently, Allyson has been involved in the field of ovarian cancer for 20 years and she founded Ovarian Cancer Action in 2005. She developed the first UK ovarian cancer national awareness campaign, which was instrumental in the start-up of the charity and the formal recognition of the symptoms of ovarian cancer in the UK today. In 2009 Ovarian Cancer Action opened its Research Centre at Imperial College where there are now more than 60 researchers. She is an active member on several science and cancer related boards and a driving force for the HHMT International Forum on Ovarian Cancer, where scientists debate and prioritise new directions in research and ways to accelerate progress. She is well-known to worldwide ovarian cancer researchers and is an author of several papers, including the latest roadmap for the future of ovarian cancer research and treatment, which was published in Nature Reviews Cancer. In the 2014 New Year’s Honours List Allyson was awarded an MBE for her work.
Nathalie is currently Group Marketing Director at ICAP where she is responsible for rebranding and developing marketing strategies across all areas of ICAP.
Prior to this, she worked for Fundtech, a Global Transaction Banking Solutions Business, as Global Marketing Director. Nathalie spent 8 years at Thomson Reuters in a variety of marketing and communications roles culminating in her being appointed Head of Marketing where she developed the internal marketing and communication strategy for Thomson Reuters flagship product Thomson Reuters Eikon. Nathalie also worked for over 4 years at Temenos, a global banking software provider, where she rebranded the company. She started her career working for a start up in London in 1998.
Daniel read economics at the London School of Economics and joined Alba PLC in 1981. He became marketing director in 1983 and joined the board when the company floated in 1987.
He was chief executive of Alba PLC for seventeen years and remained a non executive director until 2012.
Daniel currently manages Budenny LLP, an active commercial property partnership, Chairs Harvard Medical Devices and is an executive Director of West Ham Holdings PLC.
John Harris, CBE
Ovarian Cancer Action grew from the Helene Harris Memorial Trust (HHMT) which was founded by John in memory of his wife, Helene Harris, who died from ovarian cancer. His vision for the HHMT was to ensure better collaboration between international scientists to enable information to be shared globally. He received an OBE in 1996 and a CBE in 2005 for his work in this field.
Jenny's career in investment banking spans nearly 30 years and many geographies and cultures. Jenny was appointed Chief Executive Officer of the Post Trade Risk and Information division in August 2015 and is a member of the GEMG. Jenny has previously worked with Standard Bank, developing the group's franchise and building sustainable relationships with clients, key stakeholders and the wider communities. Jenny won the award for Women in the City Woman of Achievement Financial Services 2011, and is a pioneer for Corporate and Social responsibility initiatives being treasurer/fundraiser/trustee/founder sponsor of many organisations.
Martin Paisner, CBE
Martin qualified as a solicitor in January 1970 and has specialised throughout his career in the areas of charity law and private client practice. Apart from work of a general estate planning nature, including the application of trusts of a domestic and offshore nature for both UK and overseas clients, he has also been instrumental in developing Berwin Leighton Paisner’s acknowledged role as a leading adviser to charities (both functional and grant-making). He is a trustee of a great many family trusts and charities.
Dr Wayne Philips
Wayne founded Double Helix in 1995 after many years of senior and international roles within the pharmaceutical industry. A Physician with post graduate qualifications in pharmaceutical medicine, Wayne was chairman of the British Association of Pharmaceutical Physicians. He has expertise in clinical development, biostatistics, regulatory affairs and medical communications.
Wayne has over 30 years' experience in the pharmaceutical industry, of which 16 years was in clinical development and medical marketing. Prior to founding Double Helix, Wayne was Medical Director, Genentech Europe, Switzerland, and was responsible for several clinical development teams in Europe. He was previously the UK and Ireland Medical Director for Sandoz Pharmaceuticals.
Emma is the CEO at Beano Studios, a new children’s entertainment business. Emma’s move to establish Beano Studios in 2015 follows her role as Managing Director at Freesat. Her early career began in the House of Commons as a parliamentary manager, she then made the move into strategy and was responsible for delivering a number of key strategic initiatives at the BBC for the director general, Greg Dkye.
Emma won the CBI Lloyds TSB First Women in Business Award for Media in 2009.
Lord Turnberg of Cheadle
Lord Turnberg is a medical professional and an author of many publications and books related to the medical and health services fields.
His experience extends to areas of research in these fields, and to maintaining a clinical practice. He has published four books and some 150 articles on medical and scientific research. He has been a peer since 2000 and sits on the Labour benches.
Professor Sir Nicholas Wright
Sir Nicholas Alcwyn Wright is centre lead at the Centre for Tumour Biology, in the Barts Cancer Institute at Charterhouse Square, where his research concentrates on the development of gastrointestinal cancer. He was knighted in the New Year Honours list for 2006 for services to medicine.